This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Shire Human Genetic Therapies, Inc., Synageva Biopharma Corporation, Takeda Pharmaceutical Company Limited. Active years: 2015-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 86 
1 out of 25 
1 out of 1,226 
Years Active: 2015-2025
Title: Jan Powell: Innovator in CNS Therapeutics
Introduction
Jan Powell is a notable inventor based in Concord, MA (US). She has made significant contributions to the field of therapeutic agents, particularly in the delivery of treatments to the central nervous system (CNS). With a total of 5 patents to her name, her work has the potential to impact many lives.
Latest Patents
One of her latest patents focuses on the CNS delivery of therapeutic agents. This invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the CNS. In some embodiments, the invention includes methods for administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease. This method involves a composition comprising a replacement enzyme for the lysosomal enzyme, addressing critical health issues associated with enzyme deficiencies.
Career Highlights
Throughout her career, Jan Powell has worked with prominent companies in the biotechnology sector. She has been associated with Shire Human Genetic Therapies, Inc. and Synageva Biopharma Corporation. Her experience in these organizations has allowed her to develop innovative solutions in genetic therapies.
Collaborations
Jan has collaborated with notable professionals in her field, including Pericles Calias and Lawrence Charnas. These partnerships have contributed to her success and the advancement of her inventions.
Conclusion
Jan Powell's work in CNS therapeutics exemplifies the impact of innovation in medicine. Her patents and collaborations highlight her commitment to improving treatment options for patients with lysosomal storage diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile